Sino Biopharmaceutical Limited (HKG:1177)
3.880
-0.070 (-1.77%)
Apr 3, 2025, 10:45 AM HKT
Sino Biopharmaceutical Revenue
In the year 2024, Sino Biopharmaceutical had annual revenue of 28.87B CNY with 10.18% growth. Sino Biopharmaceutical had revenue of 12.99B in the half year ending December 31, 2024.
Revenue
28.87B CNY
Revenue Growth
+10.18%
P/S Ratio
2.35
Revenue / Employee
1.18M CNY
Employees
24,379
Market Cap
70.63B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.87B | 2.67B | 10.18% |
Dec 31, 2023 | 26.20B | 173.25M | 0.67% |
Dec 31, 2022 | 26.03B | -835.19M | -3.11% |
Dec 31, 2021 | 26.86B | 3.21B | 13.59% |
Dec 31, 2020 | 23.65B | -586.81M | -2.42% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
WuXi Biologics | 19.87B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Alibaba Health Information Technology | 31.39B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Sino Biopharmaceutical News
- 7 months ago - Sino Biopharmaceutical Limited goes ex-dividend tomorrow - Seeking Alpha
- 1 year ago - Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln - Reuters
- 4 years ago - Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea - Forbes
- 4 years ago - Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day - Seeking Alpha